Integrated Filing — IndAS



General information about company

Scrip Code 500288
NSE Symbol MOREPENLAB
MSEI Symbol NOTLISTED
ISIN INE083A01026
Name of company MOREPEN LABORATORIES LIMITED
Type of company Main Board
Class of security Equity
Date of start of financial year 01-04-2025
Date of end of financial year 31-03-2026
Date of board meeting when results were approved 14-11-2025
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 07-11-2025
Description of presentation currency INR
Level of rounding used in financial results Lakhs
Reporting Type Quarterly
Reporting Quarter Second quarter
Nature of report standalone or consolidated Standalone
Whether results are audited or unaudited for the quarter ended Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Unaudited
Segment Reporting Single segment
Description of single segment Pharmaceuticals
Start date and time of board meeting 14-11-2025   11:30:00
End date and time of board meeting 14-11-2025   15:00:00
Whether cash flow statement is applicable on company Yes
Type of cash flow statement Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification Not applicable
Whether the company has any related party? Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure? Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of banks staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure. NA
Whether the company is a high value debt listed entity according to regulation 15 (1A)? No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?
(b) If answer to above question is No, please explain the reason for not complying.
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company? Yes
Latest Date on which RPT policy is updated 06-02-2025
Indicate Company website link for updated RPT policy of the Company https://www.morepen.com/public/img/pdf/Policy-on-Dealings-with-Related-Party-Transactions.pdf
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter? No
No. of times funds raised during the quarter
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity? No
No default



Financial Results Ind-AS

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-07-2025 01-04-2025
B Date of end of reporting period 30-09-2025 30-09-2025
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Standalone Standalone
1 Income
Revenue from operations 36,952.63 76,081.06
Other income 465.29 874.52
Total income 37,417.92 76,955.58
2 Expenses
(a) Cost of materials consumed 22,063.31 45,834.20
(b) Purchases of stock-in-trade 709.24 839.97
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade 973.19 1,956.15
(d) Employee benefit expense 4,960.57 9,629.41
(e) Finance costs 410.58 791.74
(f) Depreciation, depletion and amortisation expense 1,070.24 1,858.16
(f) Other Expenses
1 Power and Fuel 1,116.88 2,172.63
2 Travelling Expenses 411.76 837.93
3 Selling and Distribution Expenses 1,226.61 3,853.17
4 Other Expenses 2,698.72 6,270.12
Total other expenses 5,453.97 13,133.85
Total expenses 35,641.10 74,043.48
3 Total profit before exceptional items and tax 1,776.82 2,912.10
4 Exceptional items 109.59 109.59
5 Total profit before tax 1,886.41 3,021.69
6 Tax expense
7 Current tax 448.68 777.84
8 Deferred tax 0.00 0.00
9 Total tax expenses 448.68 777.84
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0.00 0.00
11 Net Profit Loss for the period from continuing operations 1,437.73 2,243.85
12 Profit (loss) from discontinued operations before tax 0.00 0.00
13 Tax expense of discontinued operations 0.00 0.00
14 Net profit (loss) from discontinued operation after tax 0.00 0.00
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0.00 0.00
16 Total profit (loss) for period 1,437.73 2,243.85
17 Other comprehensive income net of taxes (116.42) (59.65)
18 Total Comprehensive Income for the period 1,321.31 2,184.20
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent
Total profit or loss, attributable to non-controlling interests
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent
Total comprehensive income for the period attributable to owners of parent non-controlling interests
21 Details of equity share capital
Paid-up equity share capital 10,958.41 10,958.41
Face value of equity share capital 2 2
27 Details of debt securities
22 Reserves excluding revaluation reserve
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 0.26 0.41
Diluted earnings (loss) per share from continuing operations 0.26 0.41
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 0
Diluted earnings (loss) per share from discontinued operations 0 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 0.26 0.41
Diluted earnings (loss) per share from continuing and discontinued operations 0.26 0.41
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results Textual Information(1)



Disclosure of notes on financial results

Textual Information(1) 1. The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on November 14, 2025. A Limited review of the same has been carried out by the Statutory Auditors. 2. The Exceptional Items for the quarter represents the gain of Rs. 109.59 Lakhs arising from sale of equity shares at Rs. 20.03 per share in the subsidiary of the company, Dr. Morepen Limited (DML) on July 31, 2025.Since the company expects to realise its residual investments at amounts exceeding its present fair market value, no adjustment in carrying amount in accordance with 'IndAS-109 Financial Instuments' has been considered necessary as on date. 3. The shareholders of the company approved final dividend of Rs. 0.20 per equity share of the face value of Rs. 2.00 each, in their Annual General meeting held on September 6, 2025, and dividend was paid on September 22, 2025. 4. The Company is engaged in the Pharmaceutical Business Segment.



Remarks

Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Statement of Asset and Liabilities

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
Date of start of reporting period 01-04-2025
Date of end of reporting period 30-09-2025
Whether results are audited or unaudited Unaudited
Nature of report standalone or consolidated Standalone
Assets
1 Non-current assets
Property, plant and equipment 34,737.15
Capital work-in-progress 2,554.39
Investment property 0.00
Goodwill 0.00
Other intangible assets 9,467.49
Intangible assets under development 0.00
Biological assets other than bearer plants 0.00
Investments accounted for using equity method 9,783.08
Non-current financial assets
Non-current investments 0.00
Trade receivables, non-current 0.00
Loans, non-current 14.32
Other non-current financial assets 612.34
Total non-current financial assets 626.66
Deferred tax assets (net) 0.00
Other non-current assets 10,064.51
Total non-current assets 67,233.28
2 Current assets
Inventories 25,108.57
Current financial asset
Current investments 4,059.55
Trade receivables, current 30,438.68
Cash and cash equivalents 2,692.80
Bank balance other than cash and cash equivalents 528.89
Loans, current 47.96
Other current financial assets 1,227.52
Total current financial assets 38,995.40
Current tax assets (net) 0.00
Other current assets 39,632.14
Total current assets 1,03,736.11
3 Non-current assets classified as held for sale 0.00
4 Regulatory deferral account debit balances and related deferred tax Assets 0.00
Total assets 1,70,969.39
Equity and liabilities
1 Equity
Equity attributable to owners of parent
Equity share capital 10,958.41
Other equity 1,08,290.23
Total equity attributable to owners of parent 1,19,248.64
Non controlling interest
Total equity 1,19,248.64
2 Liabilities
Non-current liabilities
Non-current financial liabilities
Borrowings, non-current 1,985.21
Trade payables, non-current
(A) Total outstanding dues of micro enterprises and small enterprises 0.00
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 0.00
Total Trade payable 0.00
Other non-current financial liabilities 635.58
Total non-current financial liabilities 2,620.79
Provisions, non-current 3,703.79
Deferred tax liabilities (net) 697.66
Deferred government grants, Non-current 0.00
Other non-current liabilities 0.00
Total non-current liabilities 7,022.24
Current liabilities
Current financial liabilities
Borrowings, current 12,538.51
Trade payables, current
(A) Total outstanding dues of micro enterprises and small enterprises 16.85
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 23,112.03
Total Trade payable 23,128.88
Other current financial liabilities 3,690.31
Total current financial liabilities 39,357.70
Other current liabilities 3,484.62
Provisions, current 1,856.19
Current tax liabilities (Net) 0.00
Deferred government grants, Current 0.00
Total current liabilities 44,698.51
3 Liabilities directly associated with assets in disposal group classified as held for sale 0.00
4 Regulatory deferral account credit balances and related deferred tax liability 0.00
Total liabilities 51,720.75
Total equity and liabilites 1,70,969.39
Disclosure of notes on assets and liabilities



Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results

Amount in (Lakhs)

Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-07-2025 01-04-2025
Date of end of reporting period 30-09-2025 30-09-2025
Whether results are audited or unaudited Unaudited Unaudited
Nature of report standalone or consolidated Standalone Standalone
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
Total Segment Revenue
Less: Inter segment revenue
Revenue from operations
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
Total Profit before tax
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax
3 (Segment Asset - Segment Liabilities)
Segment Asset
Total Segment Asset
Un-allocable Assets null null
Net Segment Asset null null
4 Segment Liabilities
Segment Liabilities
Total Segment Liabilities
Un-allocable Liabilities null null
Net Segment Liabilities null null
Disclosure of notes on segments



Other Comprehensive Income

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-07-2025 01-04-2025
B Date of end of reporting period 30-09-2025 30-09-2025
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Standalone Standalone
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 Ohters -15689000 -8007000
Total Amount of items that will not be reclassified to profit and loss (156.89) (80.07)
2 Income tax relating to items that will not be reclassified to profit or loss (40.47) (20.42)
3 Amount of items that will be reclassified to profit and loss
Total Amount of items that will be reclassified to profit and loss
4 Income tax relating to items that will be reclassified to profit or loss 0.00 0.00
5 Total Other comprehensive income (116.42) (59.65)



Cash flow statement, indirect

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
A Date of start of reporting period 01-04-2025
B Date of end of reporting period 30-09-2025
C Whether results are audited or unaudited Unaudited
D Nature of report standalone or consolidated Standalone
Statement of cash flows
Cash flows from used in operating activities
Profit before tax 3,021.69
Adjustments for reconcile profit (loss)
Adjustments for finance costs 791.74
Adjustments for decrease (increase) in inventories 3,530.36
Adjustments for decrease (increase) in trade receivables, current (1,064.03)
Adjustments for decrease (increase) in trade receivables, non-current 0.00
Adjustments for decrease (increase) in other current assets 1,004.87
Adjustments for decrease (increase) in other non-current assets (109.59)
Adjustments for other financial assets, non-current 0.00
Adjustments for other financial assets, current (80.07)
Adjustments for other bank balances 0.00
Adjustments for increase (decrease) in trade payables, current (8,550.18)
Adjustments for increase (decrease) in trade payables, non-current 0.00
Adjustments for increase (decrease) in other current liabilities 0.00
Adjustments for increase (decrease) in other non-current liabilities 0.00
Adjustments for depreciation and amortisation expense 1,858.16
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss 0.00
Adjustments for provisions, current 0.00
Adjustments for provisions, non-current 0.00
Adjustments for other financial liabilities, current 0.00
Adjustments for other financial liabilities, non-current 0.00
Adjustments for unrealised foreign exchange losses gains 0.00
Adjustments for dividend income 0.00
Adjustments for interest income 0.00
Adjustments for share-based payments 0.00
Adjustments for fair value losses (gains) 0.00
Adjustments for undistributed profits of associates 0.00
Other adjustments for which cash effects are investing or financing cash flow 0.00
Other adjustments to reconcile profit (loss) 0.00
Other adjustments for non-cash items 0.00
Share of profit and loss from partnership firm or association of persons or limited liability partnerships 0.00
Total adjustments for reconcile profit (loss) (2,618.74)
Net cash flows from (used in) operations 402.95
Dividends received 0.00
Interest paid 0.00
Interest received 0.00
Income taxes paid (refund) 757.42
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) operating activities (354.47)
Cash flows from used in investing activities
Cash flows from losing control of subsidiaries or other businesses 3,064.59
Cash flows used in obtaining control of subsidiaries or other businesses 0.00
Other cash receipts from sales of equity or debt instruments of other entities 0.00
Other cash payments to acquire equity or debt instruments of other entities 0.00
Other cash receipts from sales of interests in joint ventures 0.00
Other cash payments to acquire interests in joint ventures 0.00
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships 0.00
Cash payment for investment in partnership firm or association of persons or limited liability partnerships 0.00
Proceeds from sales of property, plant and equipment 1.00
Purchase of property, plant and equipment 4,052.93
Proceeds from sales of investment property 3,699.61
Purchase of investment property 0.00
Proceeds from sales of intangible assets 0.00
Purchase of intangible assets 5,143.85
Proceeds from sales of intangible assets under development 0.00
Purchase of intangible assets under development 0.00
Proceeds from sales of goodwill 0.00
Purchase of goodwill 0.00
Proceeds from biological assets other than bearer plants 0.00
Purchase of biological assets other than bearer plants 0.00
Proceeds from government grants 0.00
Proceeds from sales of other long-term assets 0.00
Purchase of other long-term assets 1,387.09
Cash advances and loans made to other parties 0.00
Cash receipts from repayment of advances and loans made to other parties 0.00
Cash payments for future contracts, forward contracts, option contracts and swap contracts 0.00
Cash receipts from future contracts, forward contracts, option contracts and swap contracts 0.00
Dividends received 0.00
Interest received 0.00
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) investing activities (3,818.67)
Cash flows from used in financing activities
Proceeds from changes in ownership interests in subsidiaries 0.00
Payments from changes in ownership interests in subsidiaries 0.00
Proceeds from issuing shares 0.00
Proceeds from issuing other equity instruments 0.00
Payments to acquire or redeem entity's shares 0.00
Payments of other equity instruments 0.00
Proceeds from exercise of stock options 0.00
Proceeds from issuing debentures notes bonds etc 0.00
Proceeds from borrowings 6,745.76
Repayments of borrowings 118.00
Payments of lease liabilities 391.35
Dividends paid 1,085.78
Interest paid 791.74
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 64.29
Net cash flows from (used in) financing activities 4,423.18
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes 250.04
Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents 0.00
Net increase (decrease) in cash and cash equivalents 250.04
Cash and cash equivalents cash flow statement at beginning of period 2,442.76
Cash and cash equivalents cash flow statement at end of period 2,692.80





Amount in (Lakhs)

Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter)
Sr No. Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.
Details of the party (listed entity/subsidiary) entering into the transaction Details of the counterparty Type of related party transaction Details of other related party transaction Value of the related party transaction as approved by the audit committee Remarks on approval by audit committee Value of the related party transaction ratified by the audit committee Date of Audit Committee Meeting where the ratification was approved Value of transaction during the reporting period In case monies are due to either party as a result of the transaction In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments Details of the loans, inter-corporate deposits, advances or investments Notes
Name PAN Name PAN Relationship of the counterparty with the listed entity or its subsidiary Opening balance Closing balance Nature of indebtedness (loan/ issuance of debt/ any other etc.) Details of other indebtedness Cost Tenure Nature (loan/ advance/ intercorporate deposit/ investment ) Interest Rate (%) Tenure Secured/ unsecured Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
1 Morepen Laboratories Limited Dr. Morepen Limited Entities over which persons i.e., KMP/ relative of KMP having control or significant Influence Sale of goods or services 5,000.00 Transaction is in ordinary course of business & on arm length basis and repetitive in nature 2,262.35 0.00 0.00 Textual Information(1)
2 Morepen Laboratories Limited Dr. Morepen Limited Entities over which persons i.e., KMP/ relative of KMP having control or significant Influence Purchase of goods or services 1,000.00 Transaction is in ordinary course of business & on arm length basis and repetitive in nature 0.02 1,570.69 716.77 Textual Information(2)
3 Morepen Laboratories Limited Dr. Morepen Limited Entities over which persons i.e., KMP/ relative of KMP having control or significant Influence Any other transaction Reimbursement of office & rental expense 400.00 Transaction is in ordinary course of business & on arm length basis and repetitive in nature 151.82 0.00 0.00 Textual Information(3)
4 Morepen Laboratories Limited Dr. Morepen Limited Entities over which persons i.e., KMP/ relative of KMP having control or significant Influence Any other transaction Brand usage expense 750.00 Transaction is in ordinary course of business & on arm length basis and repetitive in nature 143.95 0.00 0.00 Textual Information(4)
5 Morepen Laboratories Limited Morepen Bio Inc. Wholly Owned Subsidiary Sale of goods or services 20,000.00 Transaction is in ordinary course of business & on arm length basis and repetitive in nature 5,732.04 1,617.01 5,225.89
6 Morepen Laboratories Limited Morepen RX Limited. Wholly Owned Subsidiary Sale of goods or services 5,000.00 Transaction is in ordinary course of business & on arm length basis and repetitive in nature 323.27 489.81 1,366.39
7 Morepen Laboratories Limited Morepen RX Limited. Wholly Owned Subsidiary Any other transaction Reimbursement of office & rental expense 750.00 Transaction is in ordinary course of business & on arm length basis and repetitive in nature 27.18 0.00 0.00
8 Morepen Laboratories Limited Morepen Medipath Limited Subsidiary Company Any other transaction Subscription of Share Capital _ 20.00 0.00 0.00 Textual Information(5)
9 Morepen Laboratories Limited Morepen Device Limited Wholly Owned Subsidiary Any other transaction Reimbursement of office & rental expense 10.00 Transaction is in ordinary course of business & on arm length basis and repetitive in nature 0.48 0.30 0.00
10 Morepen Laboratories Limited Morepen Device Limited Wholly Owned Subsidiary Sale of goods or services 12.00 Transaction is in ordinary course of business & on arm length basis and repetitive in nature 3.59 0.00 4.25 Textual Information(6)
11 Morepen Laboratories Limited Edit 25 Lifestyle Private Limited Entities over which persons i.e., KMP/ relative of KMP having control or significant Influence Purchase of goods or services 250.00 Transaction is in ordinary course of business & on arm length basis and repetitive in nature 75.46 6.80 32.12
12 Morepen Laboratories Limited Mr. Sushil Suri Chairman & Managing Director Remuneration 1,200.00 Transaction is in ordinary course of business & on arm length basis and repetitive in nature 137.26 39.68 25.38
13 Morepen Laboratories Limited Mr. Sanjay Suri Whole-Time Director Remuneration 700.00 Transaction is in ordinary course of business & on arm length basis and repetitive in nature 86.33 2.36 5.36
14 Morepen Laboratories Limited Mr. Ajay Kumar Sharma Chief Financial Officer Remuneration 300.00 Transaction is in ordinary course of business & on arm length basis and repetitive in nature 74.25 6.67 8.13
15 Morepen Laboratories Limited Mr. Vipul Kumar Srivastava Company Secretary Remuneration 100.00 Transaction is in ordinary course of business & on arm length basis and repetitive in nature 32.70 3.74 4.51
16 Morepen Laboratories Limited Mr. Anubhav Suri Relative of Key Management Personnel Remuneration 1,000.00 Transaction is in ordinary course of business & on arm length basis and repetitive in nature 79.68 43.67 56.08
17 Morepen Laboratories Limited Mr. Kushal Suri Relative of Key Management Personnel Remuneration 550.00 Transaction is in ordinary course of business & on arm length basis and repetitive in nature 90.64 25.41 23.60
18 Morepen Laboratories Limited Mr. Rajas Suri Relative of Key Management Personnel Remuneration 100.00 Transaction is in ordinary course of business & on arm length basis and repetitive in nature 29.97 12.40 11.06
19 Morepen Laboratories Limited Mrs. Mamta Suri Relative of Key Management Personnel Remuneration 100.00 Transaction is in ordinary course of business & on arm length basis and repetitive in nature 47.03 10.77 7.14
20 Morepen Laboratories Limited Mrs. Sunita Suri Relative of Key Management Personnel Remuneration 100.00 Transaction is in ordinary course of business & on arm length basis and repetitive in nature 28.00 3.30 4.14
21 Morepen Laboratories Limited Mrs. Shalu Suri Relative of Key Management Personnel Remuneration 100.00 Transaction is in ordinary course of business & on arm length basis and repetitive in nature 27.77 2.66 3.16
22 Morepen Laboratories Limited Mrs. Sakshi Suri Relative of Key Management Personnel Remuneration 100.00 Transaction is in ordinary course of business & on arm length basis and repetitive in nature 28.13 12.68 3.59
23 Morepen Laboratories Limited Mrs. Suhina Suri Relative of Key Management Personnel Remuneration 100.00 Transaction is in ordinary course of business & on arm length basis and repetitive in nature 22.44 2.49 2.94
24 Morepen Laboratories Limited Mrs. Bavleen Suri Relative of Key Management Personnel Remuneration 100.00 Transaction is in ordinary course of business & on arm length basis and repetitive in nature 22.44 7.81 8.84
25 Morepen Laboratories Limited Ms.Anandi Suri Relative of Key Management Personnel Remuneration 60.00 The RPT was approved by the Audit Committee 15.00 3.43 3.43 Textual Information(7)
26 Morepen Laboratories Limited Mr. Arjun Suri Relative of Key Management Personnel Remuneration 60.00 The RPT was approved by the Audit Committee 15.00 1.92 0.00 Textual Information(8)
27 Morepen Laboratories Limited Mrs. Amita Sharma Relative of Key Management Personnel Remuneration 200.00 Transaction is in ordinary course of business & on arm length basis and repetitive in nature 57.03 5.60 5.60
28 Dr. Morepen Limited Mr. Vipul Kumar Company Secretary Remuneration 25.00 Transaction is in ordinary course of business & on arm length basis and repetitive in nature 6.60 0.97 1.06 Textual Information(9)
29 Dr. Morepen Limited Happier Life Private Limited Entities over which persons i.e., KMP/ relative of KMP having control or significant Influence Any other transaction Common expense 50.00 Transaction is in ordinary course of business & on arm length basis and repetitive in nature 2.66 0.00 4.94 Textual Information(10)
30 Dr. Morepen Limited Groom Town Private Limited. Entities over which persons i.e., KMP/ relative of KMP having control or significant Influence Purchase of goods or services 1,000.00 Transaction is in ordinary course of business & on arm length basis and repetitive in nature 20.67 0.00 0.00 Textual Information(11)
31 Dr. Morepen Limited Groom Town Private Limited. Entities over which persons i.e., KMP/ relative of KMP having control or significant Influence Sale of goods or services 5,000.00 Transaction is in ordinary course of business & on arm length basis and repetitive in nature 1.68 142.88 100.15 Textual Information(12)
32 Dr. Morepen Limited Groom Town Private Limited. Entities over which persons i.e., KMP/ relative of KMP having control or significant Influence Any other transaction Common expense 1,000.00 Transaction is in ordinary course of business & on arm length basis and repetitive in nature 58.10 0.00 0.00 Textual Information(13)
33 Dr. Morepen Limited Morepen RX Limited. Fellow Subsidiary Purchase of goods or services 300.00 Transaction is in ordinary course of business & on arm length basis and repetitive in nature 1.85 0.00 0.00 Textual Information(14)
34 Dr. Morepen Limited Morepen RX Limited. Fellow Subsidiary Any other transaction Common expense 100.00 Transaction is in ordinary course of business & on arm length basis and repetitive in nature 20.69 0.00 0.00 Textual Information(15)
35 Dr. Morepen Limited Morepen RX Limited. Fellow Subsidiary Sale of goods or services 1,000.00 Transaction is in ordinary course of business & on arm length basis and repetitive in nature 1.57 16.19 9.51 Textual Information(16)
36 Morepen RX Limited. Mr.Varun Suri Whole-Time Director Remuneration 300.00 Transaction is in ordinary course of business & on arm length basis and repetitive in nature 78.90 20.95 14.56
37 Morepen Medipath Limited. Mr. Anubhav Suri Director Any other transaction Allotment of Shares _ 0.07 0.00 0.00 Textual Information(17)
38 Morepen Medipath Limited. Mr.Rajas Suri Relative of Key Management Personnel Any other transaction Allotment of Shares _ 0.07 0.00 0.00 Textual Information(18)
39 Morepen Medipath Limited. Mr. Kushal Suri Relative of Key Management Personnel Any other transaction Allotment of Shares _ 0.07 0.00 0.00 Textual Information(19)
40 Morepen Medipath Limited. Solace Investment and Financial Services Private Limited. Entities over which persons i.e., KMP/ relative of KMP having control or significant Influence Any other transaction Allotment of Shares _ 16.90 0.00 0.00 Textual Information(20)
41 Morepen Medipath Limited. Square Investment and Financial Services Private Limited Entities over which persons i.e., KMP/ relative of KMP having control or significant Influence Any other transaction Allotment of Shares _ 16.90 0.00 0.00 Textual Information(21)
42 Morepen Medipath Limited Concept Credit and Consultants Private Limited Entities over which persons i.e., KMP/ relative of KMP having control or significant Influence Any other transaction Allotment of Shares _ 15.99 0.00 0.00 Textual Information(22)
43 Dr. Morepen Limited Total Care Limited Subsidiary Company Loan _ 0.00 868.00 868.00 Textual Information(23)
44 Morepen RX Limited. Edit 25 Lifestyle Private Limited Entities over which persons i.e., KMP/ relative of KMP having control or significant Influence Purchase of goods or services 50.00 _ 0.00 0.72 0.72
45 Morepen RX Limited. ILLUMINATE LIFESTYLE PRIVATE LIMITED Entities over which persons i.e., KMP/ relative of KMP having control or significant Influence Purchase of goods or services 50.00 _ 0.00 3.09 3.09
46 Dr. Morepen Limited Quickmed Private Limited Subsidiary Company Sale of goods or services 2,000.00 Transaction is in ordinary course of business & on arm length basis and repetitive in nature 5.56 0.00 0.00 Textual Information(24)
47 Morepen Medipath Limited Sigmacheck Health Private Limited Subsidiary Company Investment None 1.00 0.00 0.00
48 Morepen Laboratories Limited Morepen Labs - FZCO Wholly Owned Subsidiary Investment _ 11.79 0.00 0.00
49 Morepen Laboratories Limited Backhome Foods and Foods Private Limited Entities over which persons i.e., KMP/ relative of KMP having control or significant Influence Sale of goods or services 660.99 Transfer/Sale of shares of Dr. Morepen Limited to related party based on the valuation report of registered valuer 660.99 0.00 0.00
50 Morepen Laboratories Limited Blueheaven Marketing Private Limited Entities over which persons i.e., KMP/ relative of KMP having control or significant Influence Sale of goods or services 1,201.80 Transfer/Sale of shares of Dr. Morepen Limited to related party based on the valuation report of registered valuer 1,201.80 0.00 0.00
51 Morepen Laboratories Limited Vignet Trading Private Limited Entities over which persons i.e., KMP/ relative of KMP having control or significant Influence Sale of goods or services 1,201.80 Transfer/Sale of shares of Dr. Morepen Limited to related party based on the valuation report of registered valuer 1,201.80 0.00 0.00
52 Quickmed Private Limited Dr. Morepen Limited Entities over which persons i.e., KMP/ relative of KMP having control or significant Influence Any other transaction Allotment of Equity Shares 3,500.00 Business/Trade advances converted into equity 800.00 0.00 0.00 Textual Information(25)
53 Quickmed Private Limited Medsin City Private Limite Entities over which persons i.e., KMP/ relative of KMP having control or significant Influence Any other transaction Allotment of Equity Shares Business/Trade advances converted into equity 118.88 0.00 0.00 Textual Information(26)
54 Quickmed Private Limited Dr. Morepen Limited Entities over which persons i.e., KMP/ relative of KMP having control or significant Influence Any other transaction Loan Availed 2,000.00 Business/Trade advances availed 800.00 0.00 0.00 Textual Information(27)
55 Quickmed Private Limited Medsin City Private Limite Entities over which persons i.e., KMP/ relative of KMP having control or significant Influence Any other transaction Loan Availed Business/Trade advances availed 118.88 0.00 0.00 Textual Information(28)
56 Dr. Morepen Limited Backhome Foods and Foods Private Limited Entities over which persons i.e., KMP/ relative of KMP having control or significant Influence Any other transaction Acquisition of equity shares of Groom Town Private Limited 4,403.80 _ 4,403.80 0.00 0.00 Textual Information(29)
57 Dr. Morepen Limited Blueheaven Marketing Private Limited Entities over which persons i.e., KMP/ relative of KMP having control or significant Influence Any other transaction Acquisition of equity shares of Groom Town Private Limited 2,850.60 _ 2,850.60 0.00 0.00 Textual Information(30)
58 Dr. Morepen Limited Vignet Trading Private Limited Entities over which persons i.e., KMP/ relative of KMP having control or significant Influence Any other transaction Acquisition of equity shares of Groom Town Private Limited 2,850.60 _ 2,850.60 0.00 0.00 Textual Information(31)
59 Dr. Morepen Limited Shivalik Pesticidies and Chemicals Private Limited Entities over which persons i.e., KMP/ relative of KMP having control or significant Influence Any other transaction Acquisition of equity shares of Groom Town Private Limited 108.16 _ 108.16 0.00 0.00 Textual Information(32)
60 Dr. Morepen Limited Silverring Drinks Private Limited Entities over which persons i.e., KMP/ relative of KMP having control or significant Influence Any other transaction Acquisition of equity shares of Groom Town Private Limited 5,089.50 _ 5,089.50 0.00 0.00 Textual Information(33)
61 Dr. Morepen Limited Backhome Foods and Foods Private Limited Entities over which persons i.e., KMP/ relative of KMP having control or significant Influence Any other transaction Allotment of Equity shraes 4,403.80 _ 4,403.80 0.00 0.00 Textual Information(34)
62 Dr. Morepen Limited Blueheaven Marketing Private Limited Entities over which persons i.e., KMP/ relative of KMP having control or significant Influence Any other transaction Allotment of Equity shraes 2,850.60 _ 2,850.60 0.00 0.00 Textual Information(35)
63 Dr. Morepen Limited Vignet Trading Private Limited Entities over which persons i.e., KMP/ relative of KMP having control or significant Influence Any other transaction Allotment of Equity shraes 2,850.60 _ 2,850.60 0.00 0.00 Textual Information(36)
64 Dr. Morepen Limited Shivalik Pesticidies and Chemicals Private Limited Entities over which persons i.e., KMP/ relative of KMP having control or significant Influence Any other transaction Allotment of Equity shraes 108.16 _ 108.16 0.00 0.00 Textual Information(37)
65 Dr. Morepen Limited Silverring Drinks Private Limited Entities over which persons i.e., KMP/ relative of KMP having control or significant Influence Any other transaction Allotment of Equity shraes 5,089.50 _ 5,089.50 0.00 0.00 Textual Information(38)
66 Morepen Laboratories Limited Morepen RX Limited. Wholly Owned Subsidiary Purchase of goods or services 1,000.00 Transaction is in ordinary course of business & on arm length basis and repetitive in nature 0.21 0.00 0.00
67 Dr. Morepen Limited Groom Town Private Limited. Entities over which persons i.e., KMP/ relative of KMP having control or significant Influence Any other transaction Sale Return 5,000.00 Transaction is in ordinary course of business & on arm length basis and repetitive in nature 4.66 0.00 0.00 Textual Information(39)
68 Morepen Laboratories Limited Quickmed Private Limited Subsidiary Company Any other transaction Trade Advance - 75.00 0.00 75.00 Textual Information(40)
69 Morepen Laboratories Limited Morepen Proprietary Drug Research Private Limited. Entities over which persons i.e., KMP/ relative of KMP having control or significant Influence Any other transaction Purchase of goods or services 1,000.00 - 496.00 0.00 0.00
70 Dr. Morepen Limited Quickmed Private Limited Subsidiary Company Any other transaction Trade Payable - 233.55 0.00 233.55 Textual Information(41)
Total value of transaction during the reporting period 46,111.99



Text Block

Textual Information(1) Dr. Morepen Limited ceased as subsidiary of the company with effect from July 31, 2025
Textual Information(2) Dr. Morepen Limited ceased as subsidiary of the company with effect from July 31, 2025
Textual Information(3) Dr. Morepen Limited ceased as subsidiary of the company with effect from July 31, 2025
Textual Information(4) Dr. Morepen Limited ceased as subsidiary of the company with effect from July 31, 2025
Textual Information(5) Transaction approved by the Finance Committee of the Board of Directors
Textual Information(6) The closing balance includes trade advance extended
Textual Information(7) At the 40th Annual General Meeting of the company held on 06 September, 2025 the shareholders approved the ceiling of salary to Rs. 60 Lakhs
Textual Information(8) At the 40th Annual General Meeting of the company held on 06 September, 2025 the shareholders approved the ceiling of salary to Rs. 60 Lakhs
Textual Information(9) Dr. Morepen Limited ceased as subsidiary of the company with effect from July 31, 2025
Textual Information(10) Dr. Morepen Limited ceased as subsidiary of the company with effect from July 31, 2025
Textual Information(11) Dr. Morepen Limited ceased as subsidiary of the company with effect from July 31, 2025
Textual Information(12) Dr. Morepen Limited ceased as subsidiary of the company with effect from July 31, 2025
Textual Information(13) Dr. Morepen Limited ceased as subsidiary of the company with effect from July 31, 2025
Textual Information(14) Dr. Morepen Limited ceased as subsidiary of the company with effect from July 31, 2025
Textual Information(15) Dr. Morepen Limited ceased as subsidiary of the company with effect from July 31, 2025
Textual Information(16) Dr. Morepen Limited ceased as subsidiary of the company with effect from July 31, 2025
Textual Information(17) Transaction approved by the Finance Committee of the Board of Directors
Textual Information(18) Transaction approved by the Finance Committee of the Board of Directors
Textual Information(19) Transaction approved by the Finance Committee of the Board of Directors
Textual Information(20) Transaction approved by the Finance Committee of the Board of Directors
Textual Information(21) Transaction approved by the Finance Committee of the Board of Directors
Textual Information(22) Transaction approved by the Finance Committee of the Board of Directors
Textual Information(23) On account of cessation of Dr. Morepen Limited as a subsidiary, Total Care Limired has also ceased as step down subsidiary with effect from July 31, 2025
Textual Information(24) Dr. Morepen Limited ceases to be subsidiary of the company with effect from July 31, 2025
Textual Information(25) On account of cessation of Dr. Morepen Limited as a subsidiary, Quick Med Private Limired has also ceased as step down subsidiary with effect from July 31, 2025
Textual Information(26) On account of cessation of Dr. Morepen Limited as a subsidiary, Quick Med Private Limired has also ceased as step down subsidiary with effect from July 31, 2025
Textual Information(27) On account of cessation of Dr. Morepen Limited as a subsidiary, Quick Med Private Limired has also ceased as step down subsidiary with effect from July 31, 2025
Textual Information(28) On account of cessation of Dr. Morepen Limited as a subsidiary, Quick Med Private Limired has also ceased as step down subsidiary with effect from July 31, 2025
Textual Information(29) Acquisition of equity shares in Groom Town Private Limited by DR. Morepen Limited from the related party
Textual Information(30) Acquisition of equity shares in Groom Town Private Limited by DR. Morepen Limited from the related party
Textual Information(31) Acquisition of equity shares in Groom Town Private Limited by DR. Morepen Limited from the related party
Textual Information(32) Acquisition of equity shares in Groom Town Private Limited by DR. Morepen Limited from the related party
Textual Information(33) Acquisition of equity shares in Groom Town Private Limited by DR. Morepen Limited from the related party
Textual Information(34) issuance of equity shares by Dr. Morepen Limited to the transferee of shares of GTPL, related part, as purchase consideration, share swap transaction, based on the fair exchange ratio supported by the report of registered valuer
Textual Information(35) issuance of equity shares by Dr. Morepen Limited to the transferee of shares of GTPL, related party, as purchase consideration, share swap transaction, based on the fair exchange ratio supported by the report of registered valuer
Textual Information(36) issuance of equity shares by Dr. Morepen Limited to the transferee of shares of GTPL, related party, as purchase consideration, share swap transaction, based on the fair exchange ratio supported by the report of registered valuer
Textual Information(37) issuance of equity shares by Dr. Morepen Limited to the transferee of shares of GTPL, related party, as purchase consideration, share swap transaction, based on the fair exchange ratio supported by the report of registered valuer
Textual Information(38) issuance of equity shares by Dr. Morepen Limited to the transferee of shares of GTPL, related party, as purchase consideration, share swap transaction, based on the fair exchange ratio supported by the report of registered valuer
Textual Information(39) Dr. Morepen Limited ceased as subsidiary of the company with effect from July 31, 2025
Textual Information(40) On account of cessation of Dr. Morepen Limited as a subsidiary, Quick Med Private Limired has also ceased as step down subsidiary with effect from July 31, 2025
Textual Information(41) On account of cessation of Dr. Morepen Limited as a subsidiary, Quick Med Private Limired has also ceased as step down subsidiary with effect from July 31, 2025